The beneficial effect of intravenous zoledronic acid therapy following an acute stroke in rats

Bone

Volumn 39, Issue 2, 2006, Pages 377-382

  Lee, Jong In ^a   Kim, Hye Won ^a   Rhee, Won Ihl ^a   Park, Joo Hyun ^a   Lim, Seong Hoon ^a   Im, Sun ^a   Ko, Young Jin ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Bone mineral density; Carboxy terminal telopeptide; Maximum load; Stroke; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DISEASE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FEMUR; FEMUR NECK; HEMIPLEGIA; IN VIVO STUDY; LOW DRUG DOSE; LUMBAR VERTEBRA; MEASUREMENT; MIDDLE CEREBRAL ARTERY; NONHUMAN; OSTEOLYSIS; RANDOMIZATION; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; STROKE; TIBIA;

ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CEREBROVASCULAR ACCIDENT; DENSITOMETRY, X-RAY; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMUR; IMIDAZOLES; INJECTIONS, INTRAVENOUS; LUMBAR VERTEBRAE; OSTEOCALCIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TIBIA;

EID: 33744907259     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.02.055     Document Type: Article

References (23)

1. Ramnemark A., Nyberg L., Borssen B., Olsson T., and Gustafson Y. Fractures after stroke. Osteoporos. Int. 8 (1998) 92-95
2. Ramnemark A., Nilsson M., Borssen B., and Gustafson Y. Stroke, a major and increasing risk factor for femoral neck fracture. Stroke 31 (2000) 1572-1575
3. Sato Y. Abnormal bone and calcium metabolism in patients after stroke. Arch. Phys. Med. Rehabil. 81 (2000) 117-121
4. Sato Y., Kuno H., Kaji M., Etoh K., and Oizumi K. Influence of immobilization upon calcium metabolism in the week following hemiplegic stroke. J. Neurol. Sci. 175 (2000) 135-139
5. Poole K.E., Reeve J., and Warburton E.A. Falls, fractures, and osteoporosis after stroke time to think about protection?. Stroke 33 (2002) 1432-1436
6. Russell R.G., Croucher P.I., and Rogers M.J. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos. Int. 9 (1999) S66-S80
7. Sato Y., Iwamoto J., Kanoko T., and Satoh K. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 64 (2005) 811-816
8. Body J.J., Lortholary A., Romieu G., Vigneron A.M., and Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J. Bone Miner. Res. 14 (1999) 1557-1561
9. Major P., Lortholary A., Hon J., Hon J., Abdi E., Mills G., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19 (2001) 558-567
10. Pataki A., Müller K., Green J.R., Ma Y.F., Li Q.N., and Jee W.S.S. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on cancellous bone formed before and during the treatment. Anat. Rec. 249 (1997) 458-468
11. Müller K., Wiesenberg I., Jaeggi K.A., and Green J.R. Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat. Drug Res. 48 (1998) 81-86
12. Reid I.R., Brown J.P., Burckardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346 (2002) 653-661
13. Longa E., Weinstein P., Carlson S., and Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20 (1989) 84-91
14. Hornby S.B., Evans G.P., Hornby S.L., Pataki A., Glatt M., and Green J.R. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif. Tissue Int. 72 (2003) 519-527
15. Glatt M., Pataki A., Evans G.P., Hornby S.B., and Green J.R. Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos. Int. 15 (2004) 707-715
16. Garcia J., Wagner S., Liu K., and Hu X. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 26 (1995) 627-634
17. Mosekilde L.I., Thomsen J.S., Mackey M.S., and Phipps R.J. Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 27 (2000) 639-645
18. Sato Y., Maruoka H., Honda Y., Asoh T., Fujimatsu Y., and Oizumi K. Development osteopenia in the hemiplegic finger in patients with stroke. Eur. Neurol. 36 (1996) 278-283
19. Sato Y., Maruoka H., Oizumi K., and Kikuyama M. Vitamin D deficiency and osteopenia in the hemiplegic limbs of stroke patients. Stroke 27 (1996) 2183-2187
20. Sato Y., Kuno H., Kaji M., Ohshima Y., Asoh T., and Oizumi K. Increased bone resorption during the first year following a stroke. Stroke 29 (1998) 1373-1377
21. Warden S.J., Bliziotes M.M., Wiren K.M., Eshleman A.J., and Turner C.H. Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol. Cell Endocrinol. 242 (2005) 1-9
22. Sato Y., Asoh T., Kaji M., and Oizumi K. Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. J. Bone Miner. Res. 15 (2000) 2487-2494
23. Sato Y., Fujimatsu Y., Kikuyama M., Kaji M., and Oizumic K. Influence of immobilization on bone mass and bone metabolism in hemiplegic elderly patients with a long-standing stroke. J. Neurol. Sci. 156 (1998) 205-210